Home » Newsletters » BioWorld Science

BioWorld Science

May 16, 2022

View Archived Issues

New inhibitors of G12C mutant KRAS protein identified at Amgen

Calithera Biosciences presents new L-amino acid oxidase inhibitors

Medshine Discovery patents Janus kinase inhibitors

Novel CAR-NK cells targeting CD33 show promise for AML

New compounds targeting the estrogen receptor divulged by Sanofi

Korea University Research and Business Foundation presents new apoptosis inducers

Diabetic foot ulcers hold clues to tumor suppression

CCL22-derived peptides as vaccines for cancer immunotherapy

Large animal model of USH3 disease generated by zygote injection and guide RNAs

miR30e-5p is a predictive biomarker of relapse in myasthenia gravis

MuSK-CAARTs demonstrate promising safety and activity in models of MuSK myasthenia gravis

AMP vaccine boosting enhances TCR-T cell therapy in mice with solid tumors

SOM signs licensing agreement with University of Minnesota to support muscular dystrophy work

SHP-2 inhibitor NSC-87877 ameliorates clinical symptoms of MuSK-induced myasthenia gravis

Celmatix identifies AMHR2 agonist to prevent premature menopause after chemotherapy

BioAge develops small-molecule NLRP3 inhibitors for inflammatory and age-related diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...